Compare EPM & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPM | MIST |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.9M | 176.3M |
| IPO Year | 1996 | 2019 |
| Metric | EPM | MIST |
|---|---|---|
| Price | $4.40 | $1.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $4.83 | ★ $8.00 |
| AVG Volume (30 Days) | 349.3K | ★ 1.3M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | ★ 10.08% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,229,621.00 | N/A |
| Revenue This Year | N/A | $2,915.14 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.19 | $1.00 |
| 52 Week High | $5.70 | $3.06 |
| Indicator | EPM | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 33.65 |
| Support Level | $4.18 | $1.00 |
| Resistance Level | $4.74 | $2.30 |
| Average True Range (ATR) | 0.18 | 0.13 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 24.68 | 2.46 |
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).